Provided by Tiger Trade Technology Pte. Ltd.

Amneal Pharmaceuticals, Inc.

17.95
+0.47502.72%
Volume:29.26K
Turnover:518.36K
Market Cap:5.72B
PE:37.32
High:17.99
Open:17.57
Low:17.49
Close:17.47
52wk High:19.26
52wk Low:9.32
Shares:319.00M
Float Shares:191.00M
Volume Ratio:0.90
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4808
EPS(LYR):0.2200
ROE:613.02%
ROA:8.60%
PB:173.34
PE(LYR):81.57

Loading ...

GUIDANCE: (AMRX) Amneal Pharmaceuticals Expects Full Year 2026 Revenue Range $3.10B - $3.20B, vs. FactSet Est of $3.11B

MT Newswires Live
·
Jul 30

Amneal Q2 FY26 GAAP Net Income More than Doubles to $58 Million; Revenue Rises 10% to $796 Million

Reuters
·
Jul 30

Amneal Pharmaceuticals Shares up 10.5% Premarket After Q2 Profit Beat

THOMSON REUTERS
·
Jul 30

Amneal Pharmaceuticals Q2 Revenue USD 796 Million

Reuters
·
Jul 30

Amneal Pharmaceuticals Q2 Adj. EPS $0.30 Beats $0.22 Estimate, Sales $796.197M Beat $768.206M Estimate

Benzinga Earnings
·
Jul 30

Amneal Pharmaceuticals Outlook FY Adjusted EPS USD 0.96-1.06

THOMSON REUTERS
·
Jul 30

Amneal Pharmaceuticals Q2 Adjusted EPS USD 0.3 VS. Ibes Estimate USD 0.22

THOMSON REUTERS
·
Jul 30

Amneal Pharmaceuticals Outlook FY Revenue USD 3,100-3,200 Million

THOMSON REUTERS
·
Jul 30

Amneal Pharmaceuticals Outlook FY Capex USD 150 Million

THOMSON REUTERS
·
Jul 30

Amneal Reports Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Jul 30

Goldman Sachs Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX)

TIPRANKS
·
Jul 27

Earning Preview: Amneal Pharmaceuticals, Inc. this quarter’s revenue is expected to increase by 3.18%, and institutional views are bullish

Earnings Agent
·
Jul 24

Analysts Have Conflicting Sentiments on These Healthcare Companies: Trevi Therapeutics (TRVI), Amneal Pharmaceuticals (AMRX) and Erasca (ERAS)

TIPRANKS
·
Jul 20

Amneal receives FDA approval for additional iohexol strengths, presentations

TIPRANKS
·
Jul 17

Amneal Wins FDA Approval for Additional Iohexol Injection Strengths and Vial Sizes

Reuters
·
Jul 17

Amneal Pharma - to Launch New Iohexol Injection Products in Q3 2026

THOMSON REUTERS
·
Jul 17

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

THOMSON REUTERS
·
Jul 17

Amneal Pharmaceuticals is Maintained at Buy by UBS

Dow Jones
·
Jul 15

UBS Adjusts Amneal Pharmaceuticals Price Target to $23 From $19, Maintains Buy Rating

MT Newswires Live
·
Jul 15

Amneal Pharmaceuticals price target raised to $23 from $19 at UBS

TIPRANKS
·
Jul 15